Prelude Therapeutics (PRLD) Enterprise Value (2019 - 2026)

Prelude Therapeutics has disclosed Enterprise Value across 8 years of filings, most recently posting -$144.6 million for Q1 2026.

• Enterprise Value for Q1 2026 came in at -$144.6 million, down 40.23% year-over-year; the trailing twelve-month figure through Mar 2026 was -$144.6 million (down 40.23% YoY), and the FY2025 annual result was -$103.2 million, up 25.02% from the prior year.
• Enterprise Value came in at -$144.6 million for Q1 2026 at Prelude Therapeutics, down from -$103.2 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$58.2 million in Q3 2025 to a low of -$270.2 million in Q1 2022.
• The 5-year median for Enterprise Value is -$183.9 million (2024), against an average of -$181.2 million.
• Across the five-year window, Enterprise Value soared 63.09% in 2025 and plunged 40.23% in 2026, its largest moves.
• Prelude Therapeutics' Enterprise Value stood at -$205.8 million in 2022, then retreated by 15.17% to -$237.0 million in 2023, then surged by 41.91% to -$137.7 million in 2024, then advanced by 25.02% to -$103.2 million in 2025, then slumped by 40.1% to -$144.6 million in 2026.
• The last three Enterprise Value figures came in at -$144.6 million (Q1 2026), -$103.2 million (Q4 2025), and -$58.2 million (Q3 2025), per Business Quant data.